XML 58 R46.htm IDEA: XBRL DOCUMENT v3.23.3
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Acquisitions and Cost-Reduction/Productivity Initiatives (Detail) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Oct. 01, 2023
Oct. 02, 2022
Apr. 03, 2022
Oct. 01, 2023
Oct. 02, 2022
Restructuring charges/(credits):          
Employee terminations $ 16 $ 158   $ 77 $ 293
Asset impairments 40 17   45 44
Exit costs/(credits) 15 2   44 31
Restructuring charges/(credits) [1] 71 177   165 368
Transaction costs [2] 5 0   14 42
Integration/pre-integration costs and other [3] 78 22   198 170
Restructuring charges and certain acquisition-related costs 155 199   377 580
Implementation costs [4] 116 150   298 384
Total costs associated with acquisitions and cost-reduction/productivity initiatives 276 357   696 982
Biopharma [Member]          
Restructuring charges/(credits):          
Restructuring charges/(credits) 1 62   (22) 108
Other (income)/deductions––net [Member]          
Restructuring charges/(credits):          
Net periodic benefit costs/(credits) recorded in Other (income)/deductions––net 0 0   (7) (5)
Cost of sales [Member]          
Restructuring charges/(credits):          
Additional depreciation––asset restructuring [5] 5 7   28 22
Implementation costs [4] 16 14   43 40
Selling, informational and administrative expenses [Member]          
Restructuring charges/(credits):          
Implementation costs [4] 71 136   196 344
Research and development expense [Member]          
Restructuring charges/(credits):          
Implementation costs [4] $ 29 $ 0   $ 59 $ 0
Restructuring charges and acquisition-related costs [Member] | Arena [Member]          
Restructuring charges/(credits):          
Post closing compensation expense     $ 138    
[1] Primarily represents cost-reduction initiatives. Restructuring charges/(credits) associated with Biopharma: charges of $1 million and credits of $22 million for the three and nine months ended October 1, 2023, respectively, and charges of $62 million and $108 million for the three and nine months ended October 2, 2022, respectively.
[2] Represents external costs for banking, legal, accounting and other similar services.
[3] Represents external, incremental costs directly related to integrating acquired businesses and our proposed acquisition of Seagen, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In the nine months ended October 1, 2023, integration/pre-integration costs and other were mostly related to our acquisitions of Biohaven and GBT and our proposed acquisition of Seagen. In the nine months ended October 2, 2022, integration costs and other were mostly related to our acquisition of Arena, including $138 million in payments to Arena employees in the first quarter of 2022 for the fair value of previously unvested long-term incentive awards that was recognized as post-closing compensation expense.
[4] Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.
[5] Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.